Gaspar, Diana P.Vital, JoanaLeiva, María C.Gonçalves, LídiaTaboada, PabloRemuñán-López, CarmenVítor, Jorge M. B.Almeida, António José2023-09-142023-09-142019Gaspar DP, Vital J, Leiva MC, Gonçalves LM, Taboada P, Remuñán-López C, et al. Transfection of pulmonary cells by stable pDNA -polycationic hybrid nanostructured particles. Nanomedicine [Internet]. fevereiro de 2019;14(4):407–29. Disponível em: https://www.futuremedicine.com/doi/10.2217/nnm-2018-0270http://hdl.handle.net/10451/59295© 2019 Future Medicine LtdAim: Cationically modified solid lipid nanoparticles (SLN) were investigated as plasmid DNA (pDNA) carriers and transfection agents for the pulmonary route. Materials & methods:pDNA-loaded SLN were produced using glyceryl dibehenate or tristearate as matrix lipids and chitosan as surface charge modifier, and encapsulated by spray-drying in mannitol and trehalose microspheres. Results: Nanoparticles of 200 nm, and zeta potential around +15 mV were produced. Electrophorectic analysis confirmed plasmid stability and integrity. The pDNA-loaded SLN were able to transfect the Calu-3 and A549 pulmonary cell lines, while showing low cytotoxicity. Microencapsulation of SLN yielded dry powders suitable for inhalation that protected pDNA from degradation. Conclusion: Microencapsulated SLN are a promising safe and effective carrier system for pulmonary gene delivery following pulmonary administration.engchitosangene deliveryinhalationmicroencapsulationplasmidsolid lipid nanoparticlesspray-dryingjournal article2023-02-27cv-prod-242094410.2217/nnm-2018-02702-s2.0-85061585165